Guard Therapeutics AB (publ.) today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for company’s patent application 16/085,500 directed to the biological investigational drug ROSgard as product (composition of matter). A formal approval is expected shortly, and if granted the patent is valid until 2037. The Notice of Allowance further strengthens Guard Therapeutics' patent portfolio and improves market exclusivity for ROSgard in one of the company’s key markets.
Guard Therapeutics’ investigational drug ROSgard has been shown in several preclinical studies to protect against cell and organ damage, including acute kidney injury, by counteracting oxidative stress and supporting regenerative processes. The investigational drug is being developed to treat and prevent acute kidney injuries, initially in connection with cardiac surgery.
”We are pleased that the USPTO intends to grant a patent for our biological drug candidate ROSgard, which further strengthens the commercial potential of ROSgard. The Notice of Allowance reinforces our drug candidate’s unique properties and is important part of the company’s integrated patent portfolio”, Tobias Agervald, CEO of Guard Therapeutics says.